MedTrace Logo

Effects os Physiotherapeutic Rehabilitation on Function Autonomic and Inflammatory in Patients With Long Covid

NCT07046208 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-07-01

No results posted yet for this study

Summary

Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac biomarkers in patients with Long COVID. Methodology: This is a controlled clinical trial, carried out in a cardiorespiratory rehabilitation outpatient clinic, involving individuals with a clinical diagnosis of Long COVID undergoing a protocol of 20 aerobic, anaerobic and respiratory rehabilitation sessions. Heart rate variability (HRV) variables will be analyzed using linear and non-linear methods, in addition to serum levels of CKMB, LDH, ferritin and C-reactive protein. Expected results: Rehabilitation is expected to provide an improvement in autonomic function and a reduction in inflammatory and cardiac markers, contributing to the understanding of the pathophysiological mechanisms of Long COVID and helping to propose evidence-based therapeutic strategies.

Conditions

  • Long COVID
  • Heart Rate Variability (HRV)
  • Cardiac Biomarkers
  • Inflammatory Biomarkers

Interventions

OTHER

physiothreapy protocol

Aerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test).

Sponsors & Collaborators

  • Universidade do Estado do Pará

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2026-08-10
Completion
2026-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046208 on ClinicalTrials.gov